Etoposide for epidemic Kaposi's sarcoma: a phase II study.

Abstract

Fourteen untreated patients with epidemic Kaposi's sarcoma stages III and IV were treated with etoposide 150 mg/m2 on 3 consecutive days every 4 weeks. No responses were observed. Myelosuppression was severe with white blood count WHO grade 3-4 in nine patients and with platelets WHO grade 3-4 in one patient. Three patients developed opportunistic infections during therapy. It is concluded that etoposide is inactive in epidemic Kaposi's sarcoma.

• Authors: P J Bakker, S A Danner, J M Lange, K H Veenhof
• Journal: European journal of cancer & clinical oncology (Eur J Cancer Clin Oncol) Vol. 24 Issue 6 Pg. 1047-8 (Jun 1988) ISSN: 0277-5379 [Print] England
• PMID: 3409942 (Publication Type: Journal Article)

Chemical References

• Etoposide

Topics

• Adult
• Drug Evaluation
• Etoposide (adverse effects, therapeutic use)
• Humans
• Leukopenia (chemically induced)
• Sarcoma, Kaposi (drug therapy)
• Thrombocytopenia (chemically induced)